Navigation Links
Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
Date:8/8/2011

ash expenditure for the second half of 2011, a viable path forward for Contrave, the timing of and potential for success with the dispute resolution process for Contrave, and the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to succeed in the dispute resolution process for Contrave; Orexigen's ability to agree with the FDA on the design and feasibility of a cardiovascular outcomes trial, Orexigen's ability to conduct such a cardiovascular outcomes trial, Orexigen's ability to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's w
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015  Organovo Holdings, Inc. (NYSE MKT: ... breakthrough 3D bioprinting technology, announced today that the company ... 2015 Healthcare Conference, to be held in ... Keith Murphy , Chairman and Chief Executive Officer, ... advances and partnerships. Details of the presentations ...
(Date:5/26/2015)... May 26, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that the Company,s President and ... present at the Jefferies 2015 Global Healthcare ... 11:30 a.m. EDT. Dr. Cauwenbergh will present ...
(Date:5/26/2015)... May 26, 2015 For the ... Quality of Life Throughout Europe, the Middle ... Astellas Pharma EMEA is celebrating its 10 ... through the historic merger of Japanese pharmaceutical companies Yamanouchi ... committed to turning science into value for patients through ...
Breaking Medicine Technology:Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 2Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 2RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 4Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4
... symptoms of ADHD, DURHAM, N.C., Sept. 10 ... stress has been shown to significantly reduce,symptoms of ... phase 3 clinical trial conducted by Addrenex,Pharmaceuticals., ... achieved statistically,significant improvement over placebo in reducing an ...
... combination of micronutrients superior to, current ,AREDS, standard ... -, HOUSTON, Sept. 10 A landmark ... a patented,combination of antioxidants and micronutrients, enabled patients ... in the study,s,placebo arm, who received the "AREDS-type" ...
Cached Medicine Technology:Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD 2Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD 3TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 2TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 3
(Date:5/26/2015)... 26, 2015 Surging to over 674,923 ... the leading online health and wellness sites, Consumer Health ... online community. It has proven to be a ... articles, watch videos, ask questions and interact with the ... the official Consumer Health Digest YouTube Channel has offered ...
(Date:5/26/2015)... Abington is pleased to announce ... practice with seven medical professionals, has joined Abington ... site in the United States to be recognized ... the National Committee for Quality Assurance. , Family ... sick care – including routine gynecology care and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 3,000 senior ... to explore and debate the future of the connected ... Freer Logic’s steering wheel that can read a driver’s ... to control a driving simulator by mind alone just ... of Freer Logic said: “We are working on cognitive ...
(Date:5/26/2015)... CO (PRWEB) May 26, 2015 It ... diverse community foundation in Colorado. On Wednesday, May 13, ... ushered in a new era of community-based giving with ... Titled “Our Future in the Making,” the event celebrated ... The Denver Foundation to mobilize resources for good. , ...
(Date:5/26/2015)... 26, 2015 On May 26, 2015, My ... salesman and distributor Dwayne Windfall. At the start of the ... that has some unique characteristics with it, so could you ... Windfall replies saying, “I was reading the newspaper looking for ... they were looking for a person with hustle. I responded ...
Breaking Medicine News(10 mins):Health News:Consumer Health Digest Official YouTube Channel: A Reliable Source of Health Information 2Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 3Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:My Positive Perspective Broadcasts Episode with Oceans 6 to Discuss Their Role in Helping the Community 2
... TUESDAY, May 22 (HealthDay News) -- Healthier lifestyles and better ... for Americans with diabetes between 1997 and 2006, especially ... government report shows. During that time, deaths from all ... deaths caused by heart disease and stroke in this group ...
... YORK (May 22, 2012) -- Up to half of all prostate ... "fusion" gene and formation of its unique protein -- but no ... Cornell Medical College researchers have found that in these cancer cells, ... known as a chromatin, is warped in such a way that ...
... MTV programs about teenage pregnancy -- "16 and Pregnant" and ... the shows glamorized teenage pregnancy, while supporters said they discouraged ... suggests they,re both right. The study, which will appear ... female students because of the high dropout rate associated with ...
... It,s quite common for a female song sparrow to stray ... door, but a new study shows that sleeping around can ... The American Naturalist, found that offspring conceived outside ... than within-pair offspring. The findings throw a monkey wrench into ...
... (HealthDay News) -- Colonoscopies helped doctors detect a high ... the screening for the first time, a new study ... made available to otherwise healthy elderly people who have ... Grand Rapids Medical Education Partners, and colleagues from Spectrum ...
... of Environmental Health Sciences (NIEHS), part of the National ... Research Program (SRP) at the University of California, San ... grant will fund continued research on the molecular and ... and other hazardous waste sites. It is the ...
Cached Medicine News:Health News:U.S. Sees Drop in Deaths Linked to Diabetes 2Health News:U.S. Sees Drop in Deaths Linked to Diabetes 3Health News:Scientists unravel role of fusion gene in prostate cancer 2Health News:Scientists unravel role of fusion gene in prostate cancer 3Health News:Scientists unravel role of fusion gene in prostate cancer 4Health News:Viewers' family background affects how they react to MTV shows 16 and Pregnant, Teen Mom 2Health News:Viewers' family background affects how they react to MTV shows 16 and Pregnant, Teen Mom 3Health News:For monogamous sparrows, it doesn't pay to stray (but they do it anyway) 2Health News:Colonoscopy May Detect Curable Cancer in Elderly: Study 2Health News:UC San Diego Superfund Research Program receives $15 million grant renewal 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: